- Q1 2024 Embla Medical hf Earnings Call TranscriptApr 23, 2024kr30.7 (+1.99%)Earnings
- Q4 2023 Ossur hf Earnings Call TranscriptJan 30, 2024kr29.65 (+4.40%)Earnings
- Q3 2023 Ossur hf Earnings Call TranscriptOct 24, 2023kr29.3 (+2.99%)Earnings
- Q2 2023 Ossur hf Earnings Call TranscriptJul 25, 2023kr32.4 (+1.73%)Earnings
- Q1 2023 Ossur hf Earnings Call TranscriptApr 25, 2023kr30.75 (-1.76%)Earnings
- Ossur hf Corporate Analyst Meeting TranscriptMar 30, 2023
- Q4 2022 Ossur hf Earnings Call TranscriptJan 31, 2023Earnings
- Q3 2022 Ossur hf Earnings Call TranscriptOct 25, 2022kr32.95 (-1.79%)Earnings
- Q2 2022 Ossur hf Earnings Call TranscriptJul 21, 2022kr31.5 (+5.00%)Earnings
- Preliminary Q2 2022 Ossur hf Earnings Call TranscriptJul 18, 2022kr29.6Earnings
- Q1 2022 Ossur hf Earnings Call TranscriptApr 26, 2022kr36.4 (-5.45%)Earnings
- Q4 2021 Ossur hf Earnings Call TranscriptFeb 01, 2022kr40.6 (+4.10%)Earnings
- Q3 2021 Ossur hf Earnings Call TranscriptOct 26, 2021kr43.2Earnings
- Q2 2021 Ossur hf Earnings Call TranscriptJul 22, 2021kr48 (+1.27%)Earnings
- Q1 2021 Ossur hf Earnings Call TranscriptApr 27, 2021kr47.25 (+2.05%)Earnings
- Q4 2020 Ossur hf Earnings Call TranscriptFeb 02, 2021kr46.25 (+0.22%)Earnings
- Q3 2020 Ossur hf Earnings Call TranscriptOct 27, 2020kr42 (-2.33%)Earnings
- Q2 2020 Ossur hf Earnings Call TranscriptJul 23, 2020kr44.3 (+0.23%)Earnings
- Q1 2020 Ossur hf Earnings Call TranscriptApr 30, 2020kr43.65 (+1.51%)Earnings
- Q4 2019 Ossur hf Earnings Call TranscriptFeb 04, 2020kr49.55 (-0.10%)Earnings
- Full Year 2019 Ossur hf Guidance Call TranscriptJan 14, 2020
- Q3 2019 Ossur hf Earnings Call TranscriptOct 22, 2019kr45.5 (+1.11%)Earnings
- Q2 2019 Ossur hf Earnings Call TranscriptJul 25, 2019kr45.95 (+5.88%)Earnings
- Q1 2019 Ossur hf Earnings Call TranscriptApr 30, 2019kr37.3 (+5.97%)Earnings
Q1 2024 Embla Medical hf Earnings Call Transcript
Good morning, and thank you all for joining our call. With me here today is Arna, our CFO. Today will cover the financial results for the first quarter, followed by a Q&A session. Q1 was a uneventful quarter where we continued to take steps to execute on our Growthâ27 strategy.
This is the first quarter we reported Embla Medical, the establishment of Embla Medica parent entity is strategically an important milestone, a natural next step as we develop the business from being a niche product supplier to a company that is working across the whole value chain, serving individuals with chronic mobility tests as well as providing braising solutions.
And our stock market ticker is now in place. In January, we acquired the flooring dense a leading maker of lower limb Neuro of the components. This acquisition is a big step on our journey and marks our entry into Neuro Orthotics field further enhancing our ability to support individuals with a chronic mobility Champs and fully aligned with our Growthâ27 patients.
And we're
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)